These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
669 related articles for article (PubMed ID: 26475447)
21. Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. Yoshida K; Iyori M; Blagborough AM; Salman AM; Dulal P; Sala KA; Yamamoto DS; Khan SM; Janse CJ; Biswas S; Yoshii T; Yusuf Y; Tokoro M; Hill AVS; Yoshida S Sci Rep; 2018 Mar; 8(1):3896. PubMed ID: 29497047 [TBL] [Abstract][Full Text] [Related]
22. Malaria vaccines: focus on adenovirus based vectors. Schuldt NJ; Amalfitano A Vaccine; 2012 Jul; 30(35):5191-8. PubMed ID: 22683663 [TBL] [Abstract][Full Text] [Related]
23. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Theisen M; Jore MM; Sauerwein R Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178 [TBL] [Abstract][Full Text] [Related]
24. The Development of Whole Sporozoite Vaccines for Itsara LS; Zhou Y; Do J; Grieser AM; Vaughan AM; Ghosh AK Front Immunol; 2018; 9():2748. PubMed ID: 30619241 [TBL] [Abstract][Full Text] [Related]
25. The stage-specific in vitro efficacy of a malaria antigen cocktail provides valuable insights into the development of effective multi-stage vaccines. Spiegel H; Boes A; Kastilan R; Kapelski S; Edgue G; Beiss V; Chubodova I; Scheuermayer M; Pradel G; Schillberg S; Reimann A; Fischer R Biotechnol J; 2015 Oct; 10(10):1651-9. PubMed ID: 25913888 [TBL] [Abstract][Full Text] [Related]
26. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Annoura T; Ploemen IH; van Schaijk BC; Sajid M; Vos MW; van Gemert GJ; Chevalley-Maurel S; Franke-Fayard BM; Hermsen CC; Gego A; Franetich JF; Mazier D; Hoffman SL; Janse CJ; Sauerwein RW; Khan SM Vaccine; 2012 Mar; 30(16):2662-70. PubMed ID: 22342550 [TBL] [Abstract][Full Text] [Related]
27. Novel ELISA method as exploratory tool to assess immunity induced by radiated attenuated sporozoites to decipher protective immunity. Knepper TA; Duncan EH; Savransky T; Bergmann-Leitner ES Malar J; 2017 Nov; 16(1):484. PubMed ID: 29187199 [TBL] [Abstract][Full Text] [Related]
28. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600 [TBL] [Abstract][Full Text] [Related]
29. Down-selecting circumsporozoite protein-based malaria vaccine: A comparison of malaria sporozoite challenge model. Amelia F; Iyori M; Emran TB; Yamamoto DS; Genshi K; Otsuka H; Onoue Y; Yusuf Y; Islam A; Yoshida S Parasite Immunol; 2019 May; 41(5):e12624. PubMed ID: 30883819 [TBL] [Abstract][Full Text] [Related]
30. RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally. Pringle JC; Carpi G; Almagro-Garcia J; Zhu SJ; Kobayashi T; Mulenga M; Bobanga T; Chaponda M; Moss WJ; Norris DE Sci Rep; 2018 Apr; 8(1):6622. PubMed ID: 29700348 [TBL] [Abstract][Full Text] [Related]
31. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487 [TBL] [Abstract][Full Text] [Related]
32. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Vaughan AM; Wang R; Kappe SH Hum Vaccin; 2010 Jan; 6(1):107-13. PubMed ID: 19838068 [TBL] [Abstract][Full Text] [Related]
33. The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria. Karch CP; Doll TAPF; Paulillo SM; Nebie I; Lanar DE; Corradin G; Burkhard P J Nanobiotechnology; 2017 Sep; 15(1):62. PubMed ID: 28877692 [TBL] [Abstract][Full Text] [Related]
34. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Trieu A; Kayala MA; Burk C; Molina DM; Freilich DA; Richie TL; Baldi P; Felgner PL; Doolan DL Mol Cell Proteomics; 2011 Sep; 10(9):M111.007948. PubMed ID: 21628511 [TBL] [Abstract][Full Text] [Related]
35. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2. Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062 [TBL] [Abstract][Full Text] [Related]
36. The use of transgenic parasites in malaria vaccine research. Othman AS; Marin-Mogollon C; Salman AM; Franke-Fayard BM; Janse CJ; Khan SM Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525963 [TBL] [Abstract][Full Text] [Related]
37. Analysis of genetic diversity and population structure of gene encoding cell-traversal protein for ookinetes and sporozoites (CelTOS) vaccine candidate antigen in global Plasmodium falciparum populations. Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND Infect Genet Evol; 2018 Apr; 59():113-125. PubMed ID: 29391203 [TBL] [Abstract][Full Text] [Related]
38. Malaria vaccine: a bright prospect for elimination of malaria. Bairwa M; Rajput M; Khanna P; Rohilla R; Verma R; Chawla S Hum Vaccin Immunother; 2012 Jun; 8(6):819-22. PubMed ID: 22739688 [TBL] [Abstract][Full Text] [Related]